Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.
This meta-analysis evaluated the effect of single agent brentuximab vedotin (BV) in patients with relapsed/refractory Hodgkin lymphoma (HL).



A systematic literature search was performed and included studies published from 1(st) January 2012 to 1(st) July 2015 investigating BV in patients with relapsed/refractory HL. Data was extracted and reviewed by two investigators then analyzed using the comprehensive meta-analysis version 3 software.



22 out of 4048 screened records met the eligibility criteria. These records included 903 patients. The median age of the cohort was 31 years (range: 26-45). 86% received ≥ 3 previous lines of systemic therapy. 529 (58.7%) and 232 (25.7%) underwent high dose chemotherapy and autologous and/or allogeneic stem transplantation prior of BV respectively. The overall response rate to BV was 62.7% (range: 30-100%). The complete response, partial response, stable disease and progressive disease rates were 31.8%, 35.1%, 19.5% and 11.7% respectively. The one year progression free survival and estimated one year overall survival were 47.6% and 79.5% respectively.



In this largest published pooled cohort, BV produces high responses with encouraging progression free and overall survival in relapsed/refractory HL patients. Our results enhance the role of BV in heavily pretreated HL patients.
a Department of Oncology , King Faisal Specialist Hospital and Research Center , Jeddah , Kingdom of Saudi Arabia.|b College of Medicine , Al-Faisal University , Riyadh , Kingdom of Saudi Arabia.
Reyad
R
Dada
a Department of Oncology , King Faisal Specialist Hospital and Research Center , Jeddah , Kingdom of Saudi Arabia.|b College of Medicine , Al-Faisal University , Riyadh , Kingdom of Saudi Arabia.
Jamal
J
Zekri
a Department of Oncology , King Faisal Specialist Hospital and Research Center , Jeddah , Kingdom of Saudi Arabia.
Rawan
R
Al Saadi
D000328:Adult; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic / Q000379:methods; D018450:Disease Progression; D018572:Disease-Free Survival; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies; D014184:Transplantation, Homologous
D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
Brentuximab vedotin; Hodgkin disease; Hodgkin lymphoma; adcertis